$TDOC
Teladoc Health, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022011868 Filed on August 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $611.4M $592.4M $565.4M
YoY Change 17.2% 17.74% 24.62%
Cost Of Revenue $185.6M $182.5M $187.0M
YoY Change 9.81% 13.85% 28.14%
Gross Profit $425.8M $409.9M $378.3M
YoY Change 20.75% 19.55% 22.95%
Gross Profit Margin 69.64% 69.2% 66.92%
Selling, General & Admin $346.1M $168.8M $163.3M
YoY Change 108.97% -3.58% -3.95%
% of Gross Profit 81.28% 41.18% 43.15%
Research & Development $87.82M $80.83M $87.41M
YoY Change 9.43% 0.08% 12.06%
% of Gross Profit 20.62% 19.72% 23.11%
Depreciation & Amortization $62.71M $60.09M $58.93M
YoY Change 20.81% 18.94% 21.11%
% of Gross Profit 14.73% 14.66% 15.58%
Operating Expenses $495.9M $249.6M $250.7M
YoY Change 101.7% -2.43% 1.09%
Operating Profit -$70.14M -$3.097B -$6.669B
YoY Change 15.78% 3822.27% 7776.17%
Interest Expense -$1.346M -$4.337M -$5.480M
YoY Change -92.88% -78.82% -75.2%
% of Operating Profit
Other Income/Expense, Net -$1.571M -$1.760M $724.0K
YoY Change 317.82% -911.06% -87.19%
Pretax Income -$74.65M -$3.103B -$6.674B
YoY Change -7.5% 2275.27% 5826.77%
Income Tax -$1.171M -$1.200M $400.0K
% Of Pretax Income
Net Earnings -$73.48M -$3.101B -$6.675B
YoY Change -12.88% 2217.65% 3243.13%
Net Earnings / Revenue -12.02% -523.56% -1180.6%
Basic Earnings Per Share -$0.45 -$19.22 -$41.58
Diluted Earnings Per Share -$454.3K -$19.22 -$41.58
COMMON SHARES
Basic Shares Outstanding 161.7M 161.4M 160.5M
Diluted Shares Outstanding 161.7M 161.4M 160.5M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $899.6M $883.7M $839.0M
YoY Change 8.87% 12.39% 16.1%
Cash & Equivalents $899.6M $881.2M $836.4M
Short-Term Investments $0.00 $2.539M $2.544M
Other Short-Term Assets $126.9M $7.009M $5.326M
YoY Change 32.28% -91.47% -92.7%
Inventory $59.34M $60.26M $70.65M
Prepaid Expenses $59.14M $48.95M $51.40M
Receivables $201.7M $205.4M $191.5M
Other Receivables $0.00 $21.91M $22.82M
Total Short-Term Assets $1.288B $1.257B $1.208B
YoY Change 11.26% 13.8% 17.02%
LONG-TERM ASSETS
Property, Plant & Equipment $72.46M $27.40M $28.42M
YoY Change 168.09% -2.77% -0.06%
Goodwill $4.846B $4.858B $7.900B
YoY Change -66.51% -66.39% -45.34%
Intangibles $1.854B $1.872B $1.884B
YoY Change -4.02% -4.64% -5.67%
Long-Term Investments
YoY Change
Other Assets $43.66M $37.94M $26.63M
YoY Change 144.02% 106.94% -4.9%
Total Long-Term Assets $6.816B $6.846B $9.884B
YoY Change -58.68% -58.53% -40.28%
TOTAL ASSETS
Total Short-Term Assets $1.288B $1.257B $1.208B
Total Long-Term Assets $6.816B $6.846B $9.884B
Total Assets $8.104B $8.103B $11.09B
YoY Change -54.09% -53.99% -36.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $70.78M $94.37M $47.41M
YoY Change 104.25% 124.28% 37.92%
Accrued Expenses $240.3M $141.0M $127.7M
YoY Change 59.23% 13.09% 11.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.09M $12.07M $12.66M
YoY Change
Total Short-Term Liabilities $411.4M $371.5M $306.7M
YoY Change 36.18% 34.48% 17.79%
LONG-TERM LIABILITIES
Long-Term Debt $1.542B $1.541B $1.541B
YoY Change 26.32% 27.33% 13.06%
Other Long-Term Liabilities $45.86M $1.609M $1.445M
YoY Change 3353.16% 19.54% 4.48%
Total Long-Term Liabilities $1.588B $1.609M $1.445M
YoY Change 119490.44% 19.54% 4.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $411.4M $371.5M $306.7M
Total Long-Term Liabilities $1.588B $1.609M $1.445M
Total Liabilities $2.051B $373.1M $308.1M
YoY Change 576.03% 34.41% 17.72%
SHAREHOLDERS EQUITY
Retained Earnings -$11.20B -$11.12B -$8.023B
YoY Change 693.94% 738.89% 572.92%
Common Stock $17.30B $17.24B $17.18B
YoY Change -0.57% -0.44% 0.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.053B $6.085B $9.143B
YoY Change
Total Liabilities & Shareholders Equity $8.104B $8.103B $11.09B
YoY Change -54.09% -53.99% -36.91%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$73.48M -$3.101B -$6.675B
YoY Change -12.88% 2217.65% 3243.13%
Depreciation, Depletion And Amortization $62.71M $60.09M $58.93M
YoY Change 20.81% 18.94% 21.11%
Cash From Operating Activities $63.02M $92.47M -$31.75M
YoY Change -17.72% 77.07% 76.12%
INVESTING ACTIVITIES
Capital Expenditures -$43.21M -$44.84M $3.913M
YoY Change 186.13% 254.36% 85.01%
Acquisitions $0.00
YoY Change -100.0%
Other Investing Activities $1.757M $0.00 -$3.264M
YoY Change -108.96% -100.0% 3.62%
Cash From Investing Activities -$41.45M -$44.84M -$27.57M
YoY Change 19.42% 1968.13% 71.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 634.0K -1.334M 2.816M
YoY Change -19.13% -111.75% -87.3%
NET CHANGE
Cash From Operating Activities 63.02M 92.47M -31.75M
Cash From Investing Activities -41.45M -44.84M -27.57M
Cash From Financing Activities 634.0K -1.334M 2.816M
Net Change In Cash 22.21M 46.30M -56.50M
YoY Change -47.95% -24.61% 375.53%
FREE CASH FLOW
Cash From Operating Activities $63.02M $92.47M -$31.75M
Capital Expenditures -$43.21M -$44.84M $3.913M
Free Cash Flow $106.2M $137.3M -$35.66M
YoY Change 15.85% 111.65% 77.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1421454000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161377695
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
156055090
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161002075
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154187739
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20220630#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
tdoc Fair Value Assets And Liabilities Transfers Between Fair Value Measurement Levels Amount
FairValueAssetsAndLiabilitiesTransfersBetweenFairValueMeasurementLevelsAmount
0
CY2021 tdoc Fair Value Assets And Liabilities Transfers Between Fair Value Measurement Levels Amount
FairValueAssetsAndLiabilitiesTransfersBetweenFairValueMeasurementLevelsAmount
0
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161892008
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
160469325
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-19.22
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-60.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.16
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
CY2022Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2022Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20220630#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001477449
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
161657805
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
881161000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
893480000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2539000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2537000
CY2022Q2 us-gaap Goodwill
Goodwill
4858196000
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
15095000
CY2021Q4 us-gaap Goodwill
Goodwill
14504174000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1872172000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1910278000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
49795000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46780000
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37477
dei Entity Registrant Name
EntityRegistrantName
TELADOC HEALTH, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
37940000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3705970
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20703000
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Manhattanville Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 203
dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
dei City Area Code
CityAreaCode
203
dei Local Phone Number
LocalPhoneNumber
635-2002
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
TDOC
dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12384000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
205434000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
168956000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27403000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27234000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-29864000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6285000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
6084650000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16045757000
CY2022Q2 us-gaap Inventory Net
InventoryNet
60260000
CY2021Q4 us-gaap Inventory Net
InventoryNet
73079000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
107875000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
87387000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
1257269000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1225439000
CY2022Q2 us-gaap Assets
Assets
8102775000
CY2021Q4 us-gaap Assets
Assets
17734608000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
94371000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
47257000
CY2022Q2 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
127187000
CY2021Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
102933000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
51594000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
91941000
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
86254000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
75569000
CY2022Q2 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
12073000
CY2021Q4 tdoc Advances From Financing Companies Current
AdvancesFromFinancingCompaniesCurrent
13313000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
371479000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
331013000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1609000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1492000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44274000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41773000
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3373000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3834000
CY2022Q2 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
7855000
CY2021Q4 tdoc Advances From Financing Companies Noncurrent
AdvancesFromFinancingCompaniesNoncurrent
9291000
CY2022Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55926000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
75777000
CY2022Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1533609000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1225671000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161892008
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
192660000
CY2022Q2 us-gaap Selling Expense
SellingExpense
57930000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
168238000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
160469325
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
162000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
160000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17239092000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
17473336000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-11124740000
CY2021Q2 us-gaap Selling Expense
SellingExpense
63856000
us-gaap Selling Expense
SellingExpense
116259000
us-gaap Selling Expense
SellingExpense
128649000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8102775000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17734608000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
592379000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
503139000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80826000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80759000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1157729000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
956814000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
182470000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
160273000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
369495000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
306232000
CY2022Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
164574000
CY2021Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
103221000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
298174000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
158767000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
110868000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
111216000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
215791000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
216388000
CY2022Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2892000
CY2021Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
11421000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
7399000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
17744000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
59371000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
51341000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
118304000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000000
CY2022Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3030000000
CY2021Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
3688931000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
582087000
us-gaap Costs And Expenses
CostsAndExpenses
10923660000
us-gaap Costs And Expenses
CostsAndExpenses
1120440000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3096552000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-78948000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9765931000
us-gaap Operating Income Loss
OperatingIncomeLoss
-163626000
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-31419000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-42878000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1760000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
217000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-133819000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1036000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5869000
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-20473000
us-gaap Net Income Loss
NetIncomeLoss
-9775984000
us-gaap Net Income Loss
NetIncomeLoss
-333468000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-18440000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
7265000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-4337000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-23579000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4741000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
90235000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3101461000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-9817000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-42598000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3102649000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-130623000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9776784000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-243233000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1188000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3196000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-800000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6227000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3119901000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-126554000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9799563000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-339695000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-19.22
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-60.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.16
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161377695
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
156055090
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161002075
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
154187739
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
9142610000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1395000
CY2022Q2 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4225000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56316000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-18440000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3101461000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
6084650000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16045757000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4980000
tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4225000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
120279000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-23579000
us-gaap Net Income Loss
NetIncomeLoss
-9775984000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
6084650000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
15829498000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5873000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6227000
us-gaap Net Income Loss
NetIncomeLoss
-333468000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
16001070000
us-gaap Net Income Loss
NetIncomeLoss
-9775984000
CY2021Q2 tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
20712000
tdoc Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation
5380000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-38328000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-35606000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10823000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
10539000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
85716000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7265000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-133819000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
16001070000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
15883804000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17781000
tdoc Stock Issued During Period Value Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
0
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
10539000
tdoc Recovered Excess Common Stock Issued For Acquisition Equity Impact
RecoveredExcessCommonStockIssuedForAcquisitionEquityImpact
40329000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
175716000
us-gaap Net Income Loss
NetIncomeLoss
-333468000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
118304000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
100000000
tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
1486000
tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
1663000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
6540000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5858000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5857000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
7534000
us-gaap Share Based Compensation
ShareBasedCompensation
111436000
us-gaap Share Based Compensation
ShareBasedCompensation
169270000
tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
-2528000
tdoc Deferred Income Tax Noncash Expense Benefit
DeferredIncomeTaxNoncashExpenseBenefit
83823000
tdoc Accretion Of Interest
AccretionOfInterest
1659000
tdoc Accretion Of Interest
AccretionOfInterest
32566000
tdoc Gain Loss On Extinguishment Of Debt Cash Flow Impact
GainLossOnExtinguishmentOfDebtCashFlowImpact
0
tdoc Gain Loss On Extinguishment Of Debt Cash Flow Impact
GainLossOnExtinguishmentOfDebtCashFlowImpact
-39782000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
5901000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-38000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
43948000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16573000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20195000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
26758000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-11974000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2234000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
17453000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1919000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
47417000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6455000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
17205000
tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-7266000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
56336000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3264000
tdoc Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-5833000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
216000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3150000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
267000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72404000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18198000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4980000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
60722000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
34191000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17781000
tdoc Payments For Repurchase Of Convertible Debt
PaymentsForRepurchaseOfConvertibleDebt
0
CY2021Q2 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
2400000
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
10901000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4405000
us-gaap Payments For Software
PaymentsForSoftware
69213000
us-gaap Payments For Software
PaymentsForSoftware
21508000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
50000000
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
0
tdoc Payments For Repurchase Of Convertible Debt
PaymentsForRepurchaseOfConvertibleDebt
137000
tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
5113000
tdoc Proceeds From Advances From Financing Companies
ProceedsFromAdvancesFromFinancingCompanies
7924000
tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
7789000
tdoc Payments From Customers Against Advances From Financing Companies
PaymentsFromCustomersAgainstAdvancesFromFinancingCompanies
8122000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1972000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
11031000
tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
54000
tdoc Cash Related To Tax Withholding For Share Based Compensation Net
CashRelatedToTaxWithholdingForShareBasedCompensationNet
5159000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2848000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-98000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1482000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33538000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10200000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
49531000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2119000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
869000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
893480000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
733324000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
881161000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
783724000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
564000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
52000
us-gaap Interest Paid
InterestPaid
8673000
us-gaap Interest Paid
InterestPaid
10379000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.5pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">T</b><b style="font-weight:bold;">ELADOC HEALTH, INC. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Note 1. Organization and Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” or the “Company,” and is the global leader in whole person virtual care, forging a new healthcare experience with better convenience, outcomes, and value. The Company’s mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. The Company’s principal executive office is located in Purchase, New York. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:10pt 0pt 0pt 0pt;">On October 30, 2020, the Company completed the merger with Livongo Health, Inc. (“Livongo”), a transformational opportunity to improve the delivery, access and experience of chronic healthcare for individuals around the world. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On July 1, 2020, the Company completed the acquisition of InTouch Technologies, Inc. (“InTouch”), a leading provider of enterprise telehealth solutions for hospitals and health systems.</p>
tdoc Number Of Professional Associations Consolidated As Variable Interest Entities
NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities
3
tdoc Number Of Professional Corporations Consolidated As Variable Interest Entities
NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities
12
tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
24600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the condensed consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Significant estimates and assumptions by management affect areas including the carrying value and useful life of long-lived assets (including intangible assets), the carrying value of goodwill, the capitalization and amortization of software development costs, deferred device and contract costs, sales and bad debt allowances, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees), the accounting for income taxes, contingences, litigation and related legal accruals, the accounting for stock-based </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">compensation awards, and other items as described in the Summary of Significant Accounting policies in this Quarterly Report and in the 2021 Form 10-K.</p>
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
592379000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
503139000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1157729000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
956814000
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
89600000
CY2021Q2 us-gaap Deferred Revenue
DeferredRevenue
72800000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
10200000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
18000000.0
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
58000000.0
CY2021Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
46600000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
60200000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
45500000
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
72600000
CY2022Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
13100000
CY2022Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
4378000
CY2022Q2 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
30013000
CY2021Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
22304000
CY2022Q2 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
9071000
CY2021Q4 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
6249000
CY2022Q2 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
39084000
CY2021Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
28553000
CY2021Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
28553000
tdoc Deferred Device Cost And Other Additions
DeferredDeviceCostAndOtherAdditions
29161000
tdoc Deferred Device Cost And Other Cost Of Revenue Recognized
DeferredDeviceCostAndOtherCostOfRevenueRecognized
-18630000
CY2022Q2 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
39084000
CY2022Q2 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
16952000
CY2021Q4 us-gaap Inventory Raw Materials And Purchased Parts Net Of Reserves
InventoryRawMaterialsAndPurchasedPartsNetOfReserves
26164000
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
484000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
313000
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
42824000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
46602000
CY2022Q2 us-gaap Inventory Net
InventoryNet
60260000
CY2021Q4 us-gaap Inventory Net
InventoryNet
73079000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
48947000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
38255000
CY2022Q2 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
30013000
CY2021Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
22304000
CY2022Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
21906000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
21168000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
7009000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5660000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
107875000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
87387000
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2332765000
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
460593000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1872172000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2261768000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
351490000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1910278000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
56700000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
49100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
113300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
95700000
CY2022Q2 tdoc Additional Amortization Expense Of Intangible Assets Related To Migration Strategy
AdditionalAmortizationExpenseOfIntangibleAssetsRelatedToMigrationStrategy
5800000
CY2022Q2 tdoc Additional Amortization Expense Of Intangible Assets Related To Migration Strategy Per Share
AdditionalAmortizationExpenseOfIntangibleAssetsRelatedToMigrationStrategyPerShare
0.04
tdoc Additional Amortization Expense Of Intangible Assets Related To Migration Strategy
AdditionalAmortizationExpenseOfIntangibleAssetsRelatedToMigrationStrategy
11600000
tdoc Additional Amortization Expense Of Intangible Assets Related To Migration Strategy Per Share
AdditionalAmortizationExpenseOfIntangibleAssetsRelatedToMigrationStrategyPerShare
0.07
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2958000
CY2021Q4 us-gaap Goodwill
Goodwill
14504174000
CY2020Q4 us-gaap Goodwill
Goodwill
14581255000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
0
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
64269000
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
0
CY2021 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-122306000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-15978000
CY2021 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-19044000
CY2022Q2 us-gaap Goodwill
Goodwill
4858196000
CY2021Q4 us-gaap Goodwill
Goodwill
14504174000
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6600000000
CY2022Q1 tdoc Goodwill Impairment Loss Per Share
GoodwillImpairmentLossPerShare
41.11
tdoc Additional Goodwill Impairment Loss
AdditionalGoodwillImpairmentLoss
3000000000.0
tdoc Additional Goodwill Impairment Loss Per Share
AdditionalGoodwillImpairmentLossPerShare
18.78
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9600000000
tdoc Goodwill Impairment Loss Per Share
GoodwillImpairmentLossPerShare
59.81
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
12029000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7124000
CY2022Q2 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
15258000
CY2021Q4 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
19010000
CY2022Q2 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
4277000
CY2021Q4 tdoc Other Current Liabilities Clients Guarantees
OtherCurrentLiabilitiesClientsGuarantees
3034000
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
1479000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1480000
CY2022Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3745000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3098000
CY2022Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
7037000
CY2021Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
3884000
tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
2800000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12983000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12687000
CY2022Q2 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
8963000
CY2021Q4 tdoc Other Current Liabilities Acquisition And Integration
OtherCurrentLiabilitiesAcquisitionAndIntegration
9965000
CY2022Q2 tdoc Other Current Liabilities Device Replacement Cost
OtherCurrentLiabilitiesDeviceReplacementCost
5925000
CY2021Q4 tdoc Other Current Liabilities Device Replacement Cost
OtherCurrentLiabilitiesDeviceReplacementCost
6263000
CY2022Q2 tdoc Other Current Liabilities Accrued Rebates
OtherCurrentLiabilitiesAccruedRebates
8585000
CY2021Q4 tdoc Other Current Liabilities Accrued Rebates
OtherCurrentLiabilitiesAccruedRebates
4619000
CY2022Q2 tdoc Other Current Liabilities Staff Augmentation
OtherCurrentLiabilitiesStaffAugmentation
8450000
CY2021Q4 tdoc Other Current Liabilities Staff Augmentation
OtherCurrentLiabilitiesStaffAugmentation
1858000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
34078000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26953000
CY2022Q2 tdoc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
127187000
CY2021Q4 tdoc Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
102933000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8221000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16106000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
10925000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8596000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7074000
CY2022Q2 tdoc Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
18109000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
69031000
CY2022Q2 us-gaap Convertible Debt
ConvertibleDebt
1533609000
CY2021Q4 us-gaap Convertible Debt
ConvertibleDebt
1225671000
CY2022Q2 tdoc Advances From Financing Companies Customer Payments Due Current
AdvancesFromFinancingCompaniesCustomerPaymentsDueCurrent
6856000
CY2022Q2 tdoc Advances From Financing Companies Customer Payments Due Year One
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearOne
9081000
CY2022Q2 tdoc Advances From Financing Companies Customer Payments Due Year Two
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearTwo
3682000
CY2022Q2 tdoc Advances From Financing Companies Customer Payments Due Year Three
AdvancesFromFinancingCompaniesCustomerPaymentsDueYearThree
309000
CY2022Q2 tdoc Advances From Financing Companies Customer Payments Due
AdvancesFromFinancingCompaniesCustomerPaymentsDue
19928000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
15311401
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3426978
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.88
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M25D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
242569000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1389672
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
34.36
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
427361
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
19557000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
27219
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
52.13
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4362070
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.47
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M4D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
44902000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4362070
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
27.47
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y5M4D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
44902000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2893202
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
21.30
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y8M12D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
44110000
CY2022Q2 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
23000000.0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51000000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
82970000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
111436000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
169270000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-800000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
90200000

Files In Submission

Name View Source Status
0001558370-22-011868-index-headers.html Edgar Link pending
0001558370-22-011868-index.html Edgar Link pending
0001558370-22-011868.txt Edgar Link pending
0001558370-22-011868-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tdoc-20220630.xsd Edgar Link pending
tdoc-20220630x10q.htm Edgar Link pending
tdoc-20220630x10q_htm.xml Edgar Link completed
tdoc-20220630xex10d1.htm Edgar Link pending
tdoc-20220630xex31d1.htm Edgar Link pending
tdoc-20220630xex31d2.htm Edgar Link pending
tdoc-20220630xex32d1.htm Edgar Link pending
tdoc-20220630xex32d2.htm Edgar Link pending
tdoc-20220630_cal.xml Edgar Link unprocessable
tdoc-20220630_def.xml Edgar Link unprocessable
tdoc-20220630_lab.xml Edgar Link unprocessable
tdoc-20220630_pre.xml Edgar Link unprocessable